Literature DB >> 9067333

Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake.

L Teng1, P A Crooks, P K Sonsalla, L P Dwoskin.   

Abstract

Lobeline is currently being developed as a substitution therapy for tobacco smoking cessation. Activation of CNS dopamine (DA) systems results in the reinforcing properties of nicotine. The present study compared the effects of lobeline and nicotine on rat striatum. Both lobeline and nicotine evoked [3H]overflow from striatal slices superfused in the presence of pargyline and nomifensine in the buffer. Marked DA depletion (42-67%) and a concomitant 2-fold increase in dihydroxyphenylacetic acid (DOPAC) in slices superfused with high concentrations (30-100 microM) of lobeline were observed. The effect of nicotine (10 microM) was inhibited in a concentration-dependent manner by mecamylamine (1-100 microM). However, lobeline (0.1-100 microM)-evoked [3H]overflow was calcium-independent, and was not antagonized by mecamylamine (1-100 microM), suggesting a mechanism of action other than stimulation of nicotinic receptors. Lobeline inhibited [3H]DA uptake into synaptosomes (IC50 = 80 +/- 12 microM) and vesicles (IC50 = 0.88 +/- 0.001 microM), whereas nicotine (< or =100 microM) did not inhibit synaptosomal or vesicular [3H]DA uptake. In the absence of pargyline and nomifensine in the buffer, endogenous DA was detected in superfusate only in those slices exposed to the highest concentration (100 microM) of lobeline. However, endogenous DOPAC concentration was increased in a concentration-dependent manner, indicating that lobeline exposure resulted in increased cytosolic DA which was rapidly metabolized to DOPAC. Under these conditions, lobeline (10-100 microM) also significantly depleted (66-85%) DA content; however, no change in DOPAC content was observed. The results suggest that, unlike nicotine, lobeline increases DA release by potent inhibition of DA uptake into synaptic vesicles, and a subsequent alteration in presynaptic DA storage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067333

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  57 in total

1.  The regulation of hippocampal nicotinic acetylcholine receptors (nAChRs) after a protracted treatment with selective or nonselective nAChR agonists.

Authors:  J Auta; P Longone; A Guidotti; E Costa
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

2.  The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.

Authors:  Joshua S Beckmann; Emily D Denehy; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

3.  HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum.

Authors:  Shaji Theodore; Wayne A Cass; Linda P Dwoskin; William F Maragos
Journal:  Synapse       Date:  2012-05-23       Impact factor: 2.562

4.  Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2005-10-15       Impact factor: 2.823

5.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

6.  Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Seth D Norrholm; Peter A Crooks
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

7.  Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats.

Authors:  Richard L Bell; Bill J A Eiler; Jason B Cook; Shafiqur Rahman
Journal:  Alcohol       Date:  2009-12       Impact factor: 2.405

8.  Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; John P Culver; Venumadhav Janganati; Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2016-08-02       Impact factor: 2.823

Review 9.  Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Authors:  Annette E Fleckenstein; Trent J Volz; Glen R Hanson
Journal:  Neuropharmacology       Date:  2008-07-10       Impact factor: 5.250

10.  Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.

Authors:  Guangrong Zheng; David B Horton; Narsimha Reddy Penthala; Justin R Nickell; John P Culver; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Medchemcomm       Date:  2013-03       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.